UPDATE 1-U.S. approves GSK, Xenoport drug for new use
LONDON, June 7
LONDON, June 7 (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday.
The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use.
- Tweet this
- Share this
- Digg this
- Alibaba surges 38 pct on massive demand in market debut
- PM Modi says al Qaeda will fail in India - CNN
- Eight bodies found after attack on Guinea Ebola education team
- French jets strike in Iraq, expanding U.S.-led campaign against Islamic State
- U.S. Fed's Fisher expects first rate hike in the spring - FBN